

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended: **September 30, 2024**

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission file number: **001-35731**

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**26-2123838**  
(I.R.S. Employer  
Identification No.)

**6303 Waterford District Drive  
Suite 215  
Miami, Florida 33126**  
(Address of principal executive offices)  
(Zip Code)

**(888) 776-6804**  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐  
Non-accelerated filer ☒

Smaller reporting company ☒  
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	NSPR	Nasdaq Capital Market

The number of shares of the registrant's common stock, \$0.0001 par value, outstanding as of November 8, 2024: 26,083,763

**TABLE OF CONTENTS**

	Page
<b>PART I</b>	
Item 1. <a href="#">Financial Statements</a>	F-1
Item 2. <a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	3
Item 3. <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	11
Item 4. <a href="#">Controls and Procedures</a>	11
<b>PART II</b>	
Item 1. <a href="#">Legal Proceedings</a>	11
Item 1A. <a href="#">Risk Factors</a>	11

Item 5.	<a href="#">Other Information</a>	12
Item 6.	<a href="#">Exhibits</a>	13

Item 1. Financial Statements

**INSPIREMD, INC.**  
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30, 2024

TABLE OF CONTENTS

	Page
<b>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:</b>	
<a href="#">Condensed Consolidated Balance Sheets</a>	F-2 - F-3
<a href="#">Condensed Consolidated Statements of Operations</a>	F-4
<a href="#">Condensed Consolidated Statements of Changes in Equity</a>	F-5 - F-8
<a href="#">Condensed Consolidated Statements of Cash Flows</a>	F-9
<a href="#">Notes to the Condensed Consolidated Financial Statements</a>	F-10 - F-17

**INSPIREMD, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited)  
(U.S. dollars in thousands)

	September 30, 2024	December 31, 2023
<b>ASSETS</b>		
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents	\$ 15,818	\$ 9,640
Marketable securities	24,584	29,383
Accounts receivable:		
Trade, net	1,530	1,804
Other	741	648
Prepaid expenses	1,276	578
Inventory	2,445	2,106
<b>TOTAL CURRENT ASSETS</b>	<b>46,394</b>	<b>44,159</b>
<b>NON-CURRENT ASSETS:</b>		
Property, plant and equipment, net	1,946	1,060
Operating lease right of use assets	1,145	1,473
Fund in respect of employee rights upon retirement	996	951
<b>TOTAL NON-CURRENT ASSETS</b>	<b>4,087</b>	<b>3,484</b>
<b>TOTAL ASSETS</b>	<b>\$ 50,481</b>	<b>\$ 47,643</b>

**INSPIREMD, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited)  
(U.S. dollars in thousands other than share and per share data)

	September 30, 2024	December 31, 2023
<b>LIABILITIES AND EQUITY</b>		
<b>CURRENT LIABILITIES:</b>		
Accounts payable and accruals:		
Trade	1,305	939
Other	5,960	5,081
<b>TOTAL CURRENT LIABILITIES</b>	<b>7,265</b>	<b>6,020</b>
<b>LONG-TERM LIABILITIES-</b>		
Operating lease liabilities	682	1,038
Liability for employees' rights upon retirement	1,183	1,084
<b>TOTAL LONG-TERM LIABILITIES</b>	<b>1,865</b>	<b>2,122</b>
<b>COMMITMENTS AND CONTINGENT LIABILITIES</b>		
<b>TOTAL LIABILITIES</b>	<b>9,130</b>	<b>8,142</b>
<b>EQUITY:</b>		

Common stock, par value \$0.0001 per share; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 25,719,632 and 21,841,215 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

3

2

Preferred C shares, par value \$0.0001 per share; 1,172,000 shares authorized at September 30, 2024 and December 31, 2023; 1,718 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

\*

\*

Additional paid-in capital

285,680

261,000

Accumulated deficit

(244,332)

(221,501)

Total equity

41,351

39,501

Total liabilities and equity

\$ 50,481

\$ 47,643

\*Represents an amount less than \$1 thousand

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-3

INSPIREMD, INC.

(Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except per share data)

	Three months ended September 30,		Nine months ended September 30,	
	2024	2023	2024	2023
REVENUES	\$ 1,810	\$ 1,556	\$ 5,060	\$ 4,444
COST OF REVENUES	1,396	1,118	4,023	3,142
GROSS PROFIT	414	438	1,037	1,302
OPERATING EXPENSES:				
Research and development	3,915	2,110	9,941	5,946
Selling and marketing	1,472	876	4,154	2,556
General and administrative	3,489	3,091	11,078	8,135
Total operating expenses	8,876	6,077	25,173	16,637
LOSS FROM OPERATIONS	(8,462)	(5,639)	(24,136)	(15,335)
FINANCIAL INCOME, net:	572	461	1,305	824
NET LOSS	\$ (7,890)	\$ (5,178)	\$ (22,831)	\$ (14,511)
NET LOSS PER SHARE - basic and diluted	\$ (0.16)	\$ (0.15)	\$ (0.58)	\$ (0.69)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	48,369,412	33,984,953	39,413,004	21,148,538

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-4

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

	Common stock		Series C Convertible Preferred Stock		Additional paid-in capital	Accumulated deficit	Total equity
	Shares	Amount	Shares	Amount			
BALANCE AT January 1, 2023	8,330,918	1	1,718	*	218,977	(201,585)	17,393
Net loss						(14,511)	(14,511)
Issuance of common shares, pre-funded warrants and warrants, net of \$4,635 issuance costs	10,266,270	1			37,533		37,534
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 14,019 shares	2,802,975	*			2,841		2,841
BALANCE AT September 30, 2023	21,400,163	2	1,718	*	259,351	(216,096)	43,257

\*Represents an amount less than \$1 thousand

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-5

INSPIREMD, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

(U.S. dollars in thousands, except share data)

	Common stock		Series C Convertible Preferred Stock		Additional paid-in capital	Accumulated deficit	Total equity
	Shares	Amount	Shares	Amount			
BALANCE AT July 1, 2023	21,192,204	2	1,718	*	257,729	(210,918)	46,813
Net loss						(5,178)	(5,178)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 9,749 shares	207,959	*			1,622		1,622
BALANCE AT September 30, 2023	21,400,163	2	1,718	*	259,351	(216,096)	43,257

\*Represents an amount less than \$1 thousand

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-6

INSPIREMD, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
(Unaudited)  
(U.S. dollars in thousands, except share data)

	Common stock		Series C Convertible Preferred Stock		Additional paid-in capital	Accumulated deficit	Total equity
	Shares	Amount	Shares	Amount			
BALANCE AT January 1, 2024	21,841,215	2	1,718	*	261,000	(221,501)	39,501
Net loss						(22,831)	(22,831)
Exercise of pre-funded warrants	1,728,382	*					*
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of \$1,000 issuance costs	292,996	1			16,853		16,854
Issuance of common shares, Included at the market offering net of \$1 issuance costs	12,961				35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 112,382 shares	1,844,078	*			7,792		7,792
BALANCE AT September 30, 2024	25,719,632	3	1,718	*	285,680	(244,332)	41,351

\* Represents an amount less than \$1 thousand

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-7

INSPIREMD, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
(Unaudited)  
(U.S. dollars in thousands, except share data)

	Common stock		Series C Convertible Preferred Stock		Additional paid-in capital	Accumulated deficit	Total equity
	Shares	Amount	Shares	Amount			
BALANCE AT July 1, 2024	25,196,479	3	1,718	*	283,202	(236,442)	46,763
Net loss						(7,890)	(7,890)
Exercise of pre-funded warrants	199,992	*					*
Issuance of common shares, Included at the market offering net of \$1 issuance costs	12,961				35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award	310,200				2,443		2,443
BALANCE AT September 30, 2024	25,719,632	3	1,718	*	285,680	(244,332)	41,351

\*Represents an amount less than \$1 thousand

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-8

INSPIREMD, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30	
	2024	2023
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$ (22,831)	\$ (14,511)
Adjustments required to reconcile net loss to net cash used in operating activities:		
Depreciation	205	171
Gain from sale of property, plant and equipment	-	(4)
Loss on amounts funded in respect of employee rights upon retirement	21	70
Changes in fair value of marketable securities, net of interest received	(757)	(321)
Change in liability for employees' rights upon retirement	99	16
Other financial expenses (income)	(8)	72
Change in operating right of use asset and leasing liability	(39)	(39)
Share-based compensation expenses	7,792	2,841
Decrease in interest receivable on short term deposits	-	171
Changes in operating asset and liability items:		
Decrease (increase) in prepaid expenses	(698)	179
Decrease (increase) in trade receivables	274	(11)
Increase in other receivables	(93)	(150)
Increase in inventory	(339)	(225)
Increase (decrease) in trade payables	366	(59)
Increase (decrease) in other payables	890	(399)
Net cash used in operating activities	(15,118)	(12,199)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Investment in short-term bank deposits	-	(5,500)
Purchase of property, plant and equipment	(1,091)	(166)
Proceeds from sale of property, plant and equipment	-	9
Investments in marketable securities	(14,444)	(28,838)
Proceeds from matured marketable securities	20,000	-
Withdrawal from short-term bank deposits	-	18,500
Amounts funded in respect of employee rights upon retirement	(66)	(61)
Net cash provided by (used in) investing activities	4,399	(16,056)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from exercise of warrants, net of \$ 1,000 issuance costs	16,854	-
Proceeds from issuance of shares and warrants, net	35	37,534
Net cash provided by financing activities	16,889	37,534
<b>EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b>	<b>8</b>	<b>(72)</b>
<b>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>6,178</b>	<b>9,207</b>
<b>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</b>	<b>9,640</b>	<b>4,632</b>
<b>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</b>	<b>\$ 15,818</b>	<b>\$ 13,839</b>
<b>SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:</b>		
Acquisition of right-of-use assets by means of lease liabilities	-	419
Non-cash lease incentive	-	45
Decrease in right-of-use assets and lease liabilities due to shortening lease term	-	131

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-9

**INSPIREMD, INC.**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

**NOTE 1 - DESCRIPTION OF BUSINESS**

**a. General**

InspireMD, Inc., a Delaware corporation (the "Company"), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures.

The Company's carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.

The Company markets its products through distributors in international markets, mainly in Europe.

**b. Liquidity**

The Company has an accumulated deficit as of September 30, 2024, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company's current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months. Therefore, there is substantial doubt about the Company's ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

Management's plans include the continued commercialization of the Company's product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.

### c. Risks Related to the Company's Operations in Israel

In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In addition, since the commencement of these events, there have been continued hostilities along Israel's northern border with Lebanon (with the Hezbollah terror organization), Israel's southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations, including its production facility, are located in Israel. Currently, such activities in Israel remain largely unaffected.

During the nine and three months ended September 30, 2024, the impact of this war on the Company's results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.

F-10

## NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2023. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2023, as found in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 5, 2024. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the entire fiscal year.

## NOTE 3 - RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS

### Recently adopted accounting pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06 "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815 – 40)." This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company adopted the provisions of this update as of January 1, 2024 with no material impact on its consolidated financial statements.

### Recently issued accounting pronouncement, not yet adopted

- 1) In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under Accounting Standards Codification ("ASC") 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity's financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures.
- 2) In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

F-11

## NOTE 4 – FAIR VALUE MEASUREMENTS

Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The Company's financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

As of September 30, 2024			
Total	Level 1	Level 2	Level 3

<b>Assets:</b>				
Cash equivalents-				
Money market funds	\$ 2,677	\$ 2,677	\$ -	\$ -
Marketable securities-				
U.S. government bonds	\$ 24,584	\$ -	\$ 24,584	\$ -

**As of December 31, 2023**  
**(\$ in thousands)**

<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
--------------	----------------	----------------	----------------

<b>Assets:</b>				
Cash equivalents-				
Money market funds	\$ 7,094	\$ 7,094	\$ -	\$ -
Marketable securities-				
U.S. government bonds	\$ 29,383	\$ -	\$ 29,383	\$ -

The Company's debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

The cost of marketable securities as of September 30, 2024, is \$ 23,919 thousand.

The cost of Marketable securities as of December 31, 2023 is \$ 28,727 thousand.

F-12

## NOTE 5 - MARKETABLE SECURITIES

The following table sets forth the Company's marketable securities for the indicated period:

	<b>September 30, 2024</b>	<b>December 31, 2023</b>
	<b>(\$ in thousands)</b>	
U.S. government bonds	\$ 24,584	\$ 29,383

The following table summarizes the fair value of the Company's marketable securities classified by maturity as of September 30, 2024, and December 31, 2023:

	<b>September 30, 2024</b>	<b>December 31, 2023</b>
	<b>(\$ in thousands)</b>	
Amounts maturing within one year	\$ 24,584	\$ 24,523
Amounts maturing after one year through two years	-	4,860
	<u>\$ 24,584</u>	<u>\$ 29,383</u>

The table below sets forth a summary of the changes in the fair value of the Company's marketable securities for the nine months period ended September 30, 2024:

	<b>Nine months ended September 30, 2024</b>	<b>Nine months ended September 30, 2023</b>
	<b>(\$ in thousands)</b>	
Balance at beginning of the period	\$ 29,383	-
Additions	14,444	28,838
Maturity	(20,000)	
Interest received	(217)	
Changes in fair value during the period	974	321
Balance at end of the period	<u>24,584</u>	<u>29,159</u>

The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis.

## NOTE 6 - EQUITY:

### 1) Exercise of Series H Warrant

The Series H Warrants have a term of the earlier of (i) five years from the date of issuance and (ii) (A) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-GUARDIANS pivotal trial.

Following the announcement on May 28, 2024 of the one year follow up study results from the Company's C-GUARDIANS pivotal trial, the Series H warrants for the purchase of 12,914,086 shares of common stock were exercised in full into 292,996 shares of common stock and pre-funded warrants exercisable into 12,621,090 shares of common stock. The net proceeds to the Company from the exercise of the Series H warrants were \$16.9 million after deduction of placement agent fees of \$ 1 million. The Series H warrants, each exercisable at \$1.3827 per share of common stock and \$1.3826 per pre-funded warrant, were issued as part of the private placement financing that the Company consummated on May 15, 2023.

F-13

## 2) ATM Offering

The Company maintains an at-the-market ("ATM") facility with Piper Sandler & Co. ("Piper") pursuant to an Equity Distribution Agreement entered into in May 2024. In accordance with the agreement, the Company is entitled, at its sole discretion, to offer and sell through or to Piper Sandler, acting as a sales agent, shares of its common stock having an aggregate offering price of up to \$17.0 million throughout the period during which the ATM facility remains in effect. The Company has agreed to pay Piper a commission of 3.0% of the gross proceeds from the sale of shares of common stock under the ATM facility. As of nine months ended September 30, 2024, 12,961 shares of common stock have been sold under the ATM program for total gross proceeds of approximately \$35 thousand and total fees of approximately \$ 1 thousand.

- 3) During the nine months ended September 30, 2024, the Company issued a total of 1,728,382 shares of its common stock in connection with the exercise of Pre-Funded Warrants to purchase 1,728,390 shares of common stock of which 200,000 Pre-Funded were exercised to 199,992 shares of its common stock on a cashless basis. As of September 30, 2024, there are Pre-Funded Warrants to purchase an aggregate of 26,147,323 shares of common stock outstanding.
- 4) As of September 30, 2024, there were 1,718 shares of Series C Preferred Stock outstanding, convertible into an aggregate of 7,952 shares of the company's common stock with a total stated value of \$10,997.
- 5) As of September 30, 2024, the Company has outstanding warrants to purchase an aggregate of 40,268,464 shares of common stock as follows:

	Number of underlying Common stock	Exercise price	Expiration date
Series F Warrants	433,878	\$ 7.4250	June 5, 2025- October 16, 2025
Series G Warrants	1,092,344	\$ 10.230	February 8, 2026
Series I Warrants	12,914,078	\$ 1.3827	*
Series J Warrants	12,914,086	\$ 1.3827	*
Series K Warrants	12,914,078	\$ 1.3827	*
Total Warrants	40,268,464		

\* The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company's announcement of receipt of Premarket Approval from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

During the nine months ended September 30, 2024, a total of 213,458 warrants expired.

- 6) As of September 30, 2024, the Company had 155,000,000 authorized shares of capital stock, par value \$0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of "blank check" preferred stock.

F-14

- 7) On September 30, 2024, the compensation committee of the Company's board of directors approved the InspireMD, Inc. 2024 Inducement Plan (the "2024 Inducement Plan") to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual's entry into employment with the Company.
- 8) During the nine months ended September 30, 2024, the Company granted 1,944,603 restricted shares of the Company's common stock to employees and directors. The shares to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The shares to directors are subject to a one-year vesting period.

The fair value of the above restricted shares was approximately \$ 5.83 million.

- 9) During the nine months ended September 30, 2024, the Company granted 563,499 restricted share units of the Company's common stock to the chief executive officer (CEO). The shares are subject to a three-year vesting period, with one-third of such awards vesting each year.

The fair value of the above restricted share units was approximately \$ 1.77 million.

- 10) During the nine months ended September 30, 2024, the Company granted to employees and directors options to purchase a total of 761,114 shares of the Company's common stock. The options have exercise prices ranging from \$2.44-\$3.14 per share, which was the fair market value of the Company's common stock on the respective dates of the grant. The options to employees are subject to a three-year vesting period, with one-third of such awards vesting each year. The options to directors are subject to a one-year vesting period.

In calculating the fair value of the above options, the Company used the following assumptions: dividend yield of 0% and expected term of 5.5-6.5 years; expected volatility ranging from 93.18%-119.38%; and risk-free interest rate ranging from 3.93%-4.44%.

The fair value of the above options, using the Black-Scholes option-pricing model, was approximately \$ 1.94 million.

- 11) On April 1, 2024, the Company granted to consultants options to purchase a total of 125,000 shares of the Company's common stock. The options have an exercise price of \$2.37 per share, which was the fair market value of the Company's common stock on the date of the grant. 25,000 options are subject to a two-year vesting period (of which 12,500 options are vesting in the first year and 12,500 options are vesting in the second year) and 100,000 options with performance conditions related to clinical activities.

In calculating the fair value of the above options, the Company used the following assumptions: dividend yield of 0%; expected volatility ranging from 96.01%-100.76%; and risk-free interest rate ranging from 4.33%-4.34%.

The fair value of the above options, using the Black-Scholes option-pricing model, was \$ 233,169.

## NOTE 7 – RELATED PARTIES TRANSACTIONS

During the nine and three months ended September 30, 2024, a member of the immediate family of the CEO provided certain administrative services in connection with the Company's expansion to the U.S. in the amount of \$55,000 and \$25,000, respectively.

**NOTE 8 - NET LOSS PER SHARE:**

Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes the effect of potential dilution of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive.

For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the nine and three-month periods ended September 30, 2024, we had weighted average pre-funded warrants of 19,016,286 and 26,199,497, respectively, which were used in the computations of net loss per share for the nine and three-month periods.

F-15

The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock excluded from the calculations of diluted loss per share were 48,619,222 and 59,753,458 as of September 30, 2024 and 2023, respectively. This amount includes 3,979,486 and 3,073,821 of unvested restricted stock included in the number of issued and outstanding shares as of September 30, 2024 and 2023, respectively.

**NOTE 9 - FINANCIAL INSTRUMENTS:****a. Fair value of financial instruments**

The carrying amounts of financial instruments approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments.

**b. As of September 30, 2024, and December 31, 2023, allowance for expected credit loss was immaterial.****NOTE 10- INVENTORY:**

	September 30, 2024	December 31, 2023
	(\$ in thousands)	
Finished goods	\$ 68	\$ 210
Work in process	557	562
Raw materials and supplies	1,820	1,334
	<u>\$ 2,445</u>	<u>\$ 2,106</u>

**NOTE 11 - ACCOUNTS PAYABLE AND ACCRUALS - OTHER:**

	September 30, 2024	December 31, 2023
	(\$ in thousands)	
Employees and employee institutions	2,312	2,188
Accrued vacation and recreation pay	401	287
Accrued expenses	1,437	1,115
Clinical trials accrual	1,078	744
Current Operating lease liabilities	546	557
Other	186	190
	<u>5,960</u>	<u>5,081</u>

F-16

**NOTE 12 - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES :**

Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues:

	Three months ended September 30,		Nine months ended September 30,	
	2024	2023	2024	2023
	(\$ in thousands)			
Germany	306	209	855	699
Italy	306	328	865	932
Russia	190	250	375	483
Poland	176	122	534	320
Other	832	647	2,431	2,010
	<u>\$ 1,810</u>	<u>\$ 1,556</u>	<u>\$ 5,060</u>	<u>\$ 4,444</u>

By principal customers:

	Three months ended September 30,		Nine months ended September 30,	
	2024	2023	2024	2023
Customer A	17%	13%	17%	16%
Customer B	11%	16%	7%	11%
Customer C	7%	13%	8%	10%
Customer D	10%	8%	9%	11%
Customer E	10%	8%	11%	7%

## NOTE 13 – SUBSEQUENT EVENTS

- 1) As of the approval date of these financial statements, the Company has issued an aggregate of 197,167 shares of restricted common stock pursuant to the 2024 Inducement Plan and 32,648 shares of restricted common stock under the 2021 plan.
- 2) On October 9, 2024, the Company entered into a lease agreement in Miami, Florida (the “Lease”) for the establishment of its new global headquarters. The Lease has a term of 64 months from the Commencement Date (as defined in the Lease) subject to a five-year extension in accordance with the terms of the Lease.

Under the Lease, the Company will pay the Landlord a security deposit of \$ 500 thousand. Provided the Company does not default, the security deposit will be refunded at specified intervals throughout the lease term. Additionally, the Company will pay a base rent of \$23 thousand per month for the first year, with gradual annual increases each subsequent year. The Company is also responsible for covering standard lease expenses, including applicable taxes, operating expenses, and utilities.

- 3) From October 1, 2024 through the date of the approval of these financial statements, 134,316 shares of common stock have been sold under the ATM program for total gross proceeds of approximately \$341 thousands and total fees of approximately \$ 10 thousands.

F-17

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.*

*Unless the context requires otherwise, references in this Form 10-Q to the “Company,” “InspireMD,” “we,” “our” and “us” refer to InspireMD, Inc., a Delaware corporation, and its subsidiaries.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation, including revenue growth. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

- our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern;
- our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders' ownership interests;
- market acceptance of our products;
- an inability to secure and maintain regulatory approvals for the sale of our products;
- negative clinical trial results or lengthy product delays in key markets;
- our ability to maintain compliance with the Nasdaq listing standards;
- our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products;
- our ability to adequately protect our intellectual property;
- our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;
- the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products;
- intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
- entry of new competitors and products and potential technological obsolescence of our products;
- inability to carry out research, development and commercialization plans;
- loss of a key customer or supplier;
- technical problems with our research and products and potential product liability claims;
- product malfunctions;
- price increases for supplies and components;

- insufficient or inadequate reimbursement by governmental and other third-party payers for our products;
- our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful;

- adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions;
- the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction;
- security, political and economic instability in the Middle East that could harm our business; and
- current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. For a discussion of these and other risks that relate to our business and investing in our common stock, you should carefully review the risks and uncertainties described in this Quarterly Report on Form 10-Q, and those described from time to time in our future reports filed with the Securities and Exchange Commission. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

## Overview

We are a medical device company focusing on the development and commercialization of our proprietary MicroNet™ stent platform for the treatment of carotid artery disease and other vascular disease. A stent is an expandable "scaffold-like" device, usually constructed of a metallic material, that is inserted into the lumen of the artery to create patency and revascularization of blood flow. MicroNet, a micron mesh sleeve, is attached over a stent to provide embolic protection both during and after stenting procedures.

Our CGuard™ carotid embolic prevention system ("CGuard EPS") combines MicroNet and a unique self-expandable nitinol stent in a single device for use in carotid artery revascularization. Our CGuard EPS originally received CE mark approval under Medical Device Directive 93/42/EEC ("MDD") in the European Union ("EU") in March 2013 and was fully launched in Europe in September 2015. Subsequently, we launched CGuard EPS in over 30 countries and on February 3, 2021, we executed a distribution agreement with Chinese partners for the purpose of expanding our presence in the Asian markets. In January 2024, we received CE mark recertification under the EU's Medical Device Regulation regulatory framework. Currently, we are seeking strategic partners for a potential launch of CGuard EPS in Japan and other Asian countries.

On September 8, 2020, we received approval from the U.S. Food and Drug Administration ("FDA") of our Investigation Device Exemption ("IDE"), thereby allowing us to proceed with a pivotal study of our CGuard™ Carotid Stent System, C-GUARDIANS, for prevention of stroke in patients in the United States. C-GUARDIANS is a prospective, multicenter, single-arm, pivotal study to evaluate the safety and efficacy of the CGuard™ Carotid Stent System when used to treat symptomatic and asymptomatic carotid artery stenosis in patients undergoing carotid artery stenting ("CAS"). The study, which completed enrollment in June 2023, enrolled 316 patients across 24 trial sites in the U.S. and Europe and from April 2023 included deployment of the CGuard stent using CGuard Prime, our next generation CAS stent platform.

The primary endpoint was a composite of: (1) incidence of major adverse events including Death (all-cause mortality), any Stroke, and Myocardial Infarction (DSMI) through 30-days post index procedure, or (2) ipsilateral stroke from day 31 to day 365 post-procedure. All events were adjudicated by an independent clinical events committee. The composite index was compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard. The performance goal was considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.

In November 2023, we announced positive 30-day follow up results from the C-GUARDIANS trial in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, measured from the date of the procedure through 30 days follow-up post-procedure. We anticipate reporting primary endpoint results from the C-GUARDIANS trial at the end of May 2024 that may support the submission of a premarket approval, or PMA, application in the third quarter of 2024 with a view to potential FDA approval of the CGuard Prime stent system in the first half of 2025.

On May 28, 2024, we announced positive one-year follow up results from the C-GUARDIANS trial in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a 30-day DSMI and Ipsilateral stroke between 31 and 365 days rate of 1.95% measured from procedure to 1-year follow-up.

We continue to invest in current and future potential new indications, products and manufacturing enhancements for CGuard that are expected to reduce cost of goods and/or provide the best-in-class performing delivery systems, such as CGuard Prime. In furtherance of our strategy that focuses on establishing the CGuard Carotid Stent System as a viable alternative to vascular surgery, we are developing a new transcatheter artery revascularization (TCAR) system, SwitchGuard™ neuroprotection system ("SwitchGuard NPS"), for transcatheter access and neuro protection. In addition, we intend to explore new indications for CGuard to leverage the advantages of stent design and mesh protection, well suited in labels such as acute stroke with tandem lesions.

We consider our current addressable market for our CGuard Carotid Stent System and SwitchGuard NPS to be both symptomatic and asymptomatic individuals with diagnosed high-grade carotid artery stenosis for whom intervention is preferable to medical (drug) therapy. This group includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy, as the two approaches compete for the same patient population. Assuming full penetration of the intervention caseload by CGuard, we estimate that the addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately \$1.3 billion (source: Health Research International Personal Medical Systems, Inc. September 13, 2021 Results of Update Report on Global Carotid Stenting Procedures and Markets by Major Geography and Addressable Markets and internal estimates). According to this same report and internal estimates, assuming full penetration of treatment for all individuals diagnosed with high-grade carotid artery stenosis, we estimate the total available market for CGuard Carotid Stent System and SwitchGuard NPS to be approximately \$9.3 billion, which may grow over time if expanded treatment options such as CGuard Carotid Stent System and SwitchGuard NPS lead to increased patient screening for carotid artery disease.

In October 2023, the Centers for Medicare and Medicaid Service ("CMS") issued its final National Coverage Determination ("NCD"), expanding coverage of CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market.

outcomes by way of stent performance with CGuard Carotid Stent System and SwitchGuard NPS.

We were organized in the State of Delaware on February 29, 2008.

## Recent Developments

### *One Year Results from the U.S. Investigational Device Exemption (IDE) clinical trial*

On May 28, 2024, we announced positive one-year follow up results from the C-GUARDIANS trial of the CGuard™ Carotid Stent System in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a 30-day DSMI and Ipsilateral stroke between 31 and 365 days rate of 1.95%, measured from procedure to 1-year follow-up.

### *Exercise of Series H Warrant*

Following the announcement of the one year follow up study results from the Company's C-GUARDIANS trial, Series H warrants to purchase 12,914,086 shares of common stock were exercised in full into 292,996 of shares of common stock and pre-funded warrants to purchase 12,621,090 shares of common stock. The net proceeds to the Company from the exercise of the Series H Warrants were \$16.9 million after deducting placement agent fees. The Series H warrants, each exercisable at \$1.3827 per common share and \$1.3826 per pre-funded warrant, were issued as part of the private placement financing that the Company consummated on May 15, 2023.

### *Security Situation in Israel*

In October 2023, Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel's border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel's northern border with Lebanon (with the Hezbollah terror organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the hostilities. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. Such clashes may escalate in the future into a greater regional conflict. We cannot currently predict the intensity or duration of Israel's war against Hamas, nor can we predict how this war will ultimately affect our business and operations or Israel's economy in general.

### *Submission of Premarket Approval Application*

In September 2024, the Company submitted a PMA application to the FDA seeking marketing approval for the CGuard Prime carotid stent system in the U.S.

### *Approval of Investigational Device Exemption*

In October 2024, the FDA approved the Company's IDE to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures.

### *Establishment of U.S. Headquarters*

In October 2024, we established our global headquarters in Miami, Florida to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system.

## Critical Accounting Policies

A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are more fully described in both (i) "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" and (ii) Note 2 of the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2023. There have not been any material changes to such critical accounting policies since December 31, 2023.

The currency of the primary economic environment in which our operations are conducted is the U.S. dollar (" \$" or "dollar").

## Results of Operations

### *Three months ended September 30, 2024, compared to the three months ended September 30, 2023*

**Revenues.** For the three months ended September 30, 2024, revenue increased by \$254,000, or 16.3%, to \$1,810,000, from \$1,556,000 during the three months ended September 30, 2023. This increase was predominantly driven by growth in existing and new markets.

With respect to geographical regions, the increase in revenue was primarily attributable to a \$142,000 increase in Europe, a \$109,000 increase in Asia and a \$13,000 increase in the Middle East, all for reasons mentioned in the paragraph above. This increase was offset by a \$7,000 decrease in Latin America.

**Gross Profit.** For the three months ended September 30, 2024, gross profit (revenue less cost of revenues) decreased by \$24,000, or 5.6%, to \$414,000, from \$438,000 during the three months ended September 30, 2023. This decrease in gross profit resulted from a \$24,000 increase in miscellaneous expense. Gross margin (gross profits as a percentage of revenue) decreased to 22.9% during the three months ended September 30, 2024, from 28.1% during the three months ended September 30, 2023, driven by the factors mentioned above.

**Research and Development Expenses.** For the three months ended September 30, 2024, research and development expenses increased by \$1,805,000, or 85.5%, to \$3,915,000, from \$2,110,000 during the three months ended September 30, 2023. This increase resulted primarily due to an increase of \$1,016,000 of SwitchGuard NPS development and regulatory approval process including expenses related to the IDE application for the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System, an increase in compensation expenses of \$670,000, mainly due to an increase of share-based compensation-related expenses and due to the hiring of the Executive Vice President and General Manager of North America in connection with our expansion plans in the United States, an increase of \$140,000 related to an early feasibility study of CGuard Prime for the treatment

of acute stroke patients with tandem lesions and an increase of \$224,000 in miscellaneous expenses. These increases were offset by a decrease of \$245,000 in expenses associated with the C-Guardians FDA Study as the one-year follow-up finalized in the second quarter of 2024 and the submission this quarter of the PMA application to the FDA.

***Selling and Marketing Expenses.*** For the three months ended September 30, 2024, selling and marketing expenses increased by \$596,000, or 68.0%, to \$1,472,000, from \$876,000 during the three months ended September 30, 2023. This increase resulted primarily from an increase in compensation expenses of \$524,000 as the Company build its U.S. commercial infrastructure to enter the U.S. market and an increase of \$72,000 in miscellaneous expenses.

***General and Administrative Expenses.*** For the three months ended September 30, 2024, general and administrative expenses increased by \$398,000, or 12.9%, to \$3,489,000, from \$3,091,000 during the three months ended September 30, 2023. This increase resulted primarily from an increase in compensation expenses of \$354,000, mainly due to an increase of share-based compensation-related expenses and an increase of \$44,000 in miscellaneous expenses.

---

7

***Financial Income.*** For the three months ended September 30, 2024, financial income increased by \$111,000 or 24.1%, to \$572,000, from \$461,000 during the three months ended September 30, 2023. The increase in financial income primarily resulted from a \$91,000 increase in interest income from investment in marketable securities, money market funds and short-term bank deposits.

***Tax Expenses.*** For the three months ended September 30, 2024, there was no material change in our tax expenses as compared to the three months ended September 30, 2023.

***Net Loss.*** Our net loss increased by \$2,712,000, or 52.4%, to \$7,890,000, for the three months ended September 30, 2024, from \$5,178,000 during the three months ended September 30, 2023. The increase in net loss resulted primarily from an increase of \$2,799,000 in operating expenses.

***Nine months ended September 30, 2024, compared to the Nine months ended September 30, 2023***

***Revenues.*** For the nine months ended September 30, 2024, revenue increased by \$616,000, or 13.9%, to \$5,060,000 from \$4,444,000 during the nine months ended September 30, 2023. This increase was mainly due to growth in existing and new markets, partially offset by a reduction in clinical trial revenue driven by the conclusion of C-GUARDIANS enrollment in June 2023.

With respect to geographical regions, the increase in revenue was primarily attributable to a \$614,000 increase in Europe, a \$79,000 increase in Asia, a \$22,000 increase in Latin America and \$6,000 in other territories for reasons mentioned above. This increase was offset by a \$104,000 decrease in the United States as we completed in June 2023 the enrollment of all patients in our C-Guardians IDE clinical trial.

***Gross Profit.*** For the nine months ended September 30, 2024, gross profit (revenue less cost of revenues) decreased by 20.4%, or \$265,000, to \$1,037,000, compared to a \$1,302,000 for the same period in 2023. This decrease in gross profit resulted from a \$744,000 increase in material and labor costs. This increase in cost was mainly due to higher sales volume, increased compensation expense for new and current employees, additional space to build capacity for anticipated increased volume requirements and additional training expenses. In addition, the increase resulted from \$78,000 related to production facility downtime for maintenance, write-offs of \$58,000 and \$3,000 in miscellaneous expense. This decrease was offset by an increase of the revenues of \$616,000 as described above.

Gross margin (gross profits as a percentage of revenue) decreased to 20.5% during the nine months ended September 30, 2024, from 29.3% during the nine months ended September 30, 2023, driven by the factors mentioned above.

***Research and Development Expenses.*** ***Research and Development Expenses.*** For the nine months ended September 30, 2024, research and development expenses increased by 67.2%, or \$3,995,000 to \$9,941,000, from \$5,946,000 during the nine months ended September 30, 2023. This increase resulted primarily from an increase in compensation expenses of \$2,032,000, mainly due to an increase of share-based compensation-related expenses and due to the hiring of the Executive Vice President and General Manager of North America in connection with our expansion plans in the United States, an increase of \$1,518,000 of SwitchGuard NPS development and regulatory approval process including expenses related to the IDE application for the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System, an increase of \$376,000 related to an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions, an increase of \$161,000 related to the establishment of operations in the United States and an increase of \$394,000 in miscellaneous expenses. These increases were offset by a decrease of \$486,000 in expenses associated with the C-Guardians FDA Study as the one-year follow-up finalized in the second quarter of 2024 and the submission this quarter of the PMA application to the U.S. FDA.

---

8

***Selling and Marketing Expenses.*** For the nine months ended September 30, 2024, selling and marketing expenses increased by 62.5%, or \$1,598,000, to \$4,154,000, from \$2,556,000 during the nine months ended September 30, 2023. This increase resulted primarily from an increase in compensation expenses of \$1,374,000 and an increase of \$224,000 in miscellaneous expenses.

***General and Administrative Expenses.*** For the nine months ended September 30, 2024, general and administrative expenses increased by 36.2%, or \$2,944,000, to \$11,079,000, from \$8,135,000 during the nine months ended September 30, 2023. This increase resulted primarily from an increase in share-based compensation expenses of \$2,868,000 and an increase of \$76,000 in miscellaneous expenses.

***Financial Income.*** For the nine months ended September 30, 2024, financial income increased by \$481,000, to \$1,305,000 of financial income, from \$824,000 of financial income during the nine months ended September 30, 2023. The increase in financial income primarily resulted from a \$478,000 increase in interest income from investment in marketable securities, money market funds and short-term bank deposits.

***Tax Expenses.*** For the nine months ended September 30, 2024, there was no material change in our tax expenses as compared to the nine months ended September 30, 2023.

***Net Loss.*** Our net loss increased by \$8,320,000, or 57.3%, to \$22,831,000, for the nine months ended September 30, 2024, from \$14,511,000 during the nine months ended September 30, 2023. The increase in net loss resulted primarily from an increase of \$8,536,000 in operating expenses and decrease of \$265,000 in gross profit, offset by an increase of \$481,000 in financial income.

## **Liquidity and Capital Resources**

We had an accumulated deficit as of September 30, 2024, of \$244 million, as well as a net loss of \$22,831,000 and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until our product, CGuard EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we believe we do not have sufficient

resources to fund operations for at least the next 12 months. Therefore, there is substantial doubt about our ability to continue as a going concern.

Our plans include continued commercialization of our products and raising capital through sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants. There are no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in commercializing our products or raising capital, we may need to reduce activities, curtail or cease operations.

In May 2023, we closed a private placement offering of 10,266,270 shares (the "Private Placement Shares") of our common stock, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 15,561,894 shares of common stock and warrants to purchase up to an aggregate of 51,656,328 shares of common stock, consisting of Series H warrants to purchase up to 12,914,086 shares of common stock (the "Series H Warrants"), Series I warrants to purchase up to 12,914,078 shares of common stock (the "Series I Warrants"), Series J warrants to purchase up to 12,914,086 shares of Common Stock (the "Series J Warrants") and Series K warrants to purchase up to 12,914,086 shares of common stock (the "Series K Warrants" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), at an offering price of \$1.6327 per Private Placement Share and associated Warrants and an offering price of \$1.6326 per Pre-Funded Warrant and associated Warrants that resulted in aggregate gross proceeds of approximately \$42.2 million, before deducting fees payable to the placement agent and other offering expenses payable by us. If the Warrants issued in the private placement offering are exercised in cash in full this would result in an additional \$71.4 million of gross proceeds.

In May 2024, we entered into an Equity Distribution Agreement with Piper Sandler & Co., as sales agent ("Piper Sandler") to which we may offer and sell, from time to time, at our option, through or to Piper Sandler up to \$17,000,000 shares of our common stock (the "ATM Program"). As of the issuance date of this report, we have sold 134,316 shares of our common stock for total gross proceeds of approximately \$341 thousands under the ATM program.

During June 2024, Series H warrants to purchase 12,914,086 shares of common stock were exercised in full into 292,996 of shares of common stock and pre-funded warrants to purchase 12,621,090 shares of common stock. The net proceeds to the Company from the exercise of the Series H Warrants were \$16.9 million after deducting placement agent fees.

#### *Nine months ended September 30, 2024 compared to the Nine months ended September 30, 2023*

*General.* At September 30, 2024, we had cash and cash equivalents of \$15,818,000 and marketable securities of \$24,584,000, as compared to cash and cash equivalents of \$9,640,000 and marketable securities of \$29,383,000 as of December 31, 2023. We have historically met our cash needs through a combination of issuing new shares, borrowing activities and product sales. Our cash requirements are generally for research and development, marketing and sales activities, finance and administrative costs, capital expenditures and general working capital.

For the nine months ended September 30, 2024, net cash used in our operating activities increased by \$2,919,000, or 23.9%, to \$15,118,000, from \$12,199,000 during the same period in 2023. The primary reason for the increase in cash used in our operating activities was an increase of \$2,276,000 in payments for third party related expenses and for professional services, an increase of \$1,506,000 in compensation costs paid during the nine months ended September 30, 2024, from \$7,332,000 in the nine months ended September 30, 2023 to \$8,838,000, a decrease of \$99,000 in interest income received from money market funds, marketable securities and bank deposits, offset in part by an increase of \$933,000 in payments received from customers.

Cash provided in our investing activities was \$4,399,000 during the nine months ended September 30, 2024, compared to cash used of \$16,056,000 during the nine months ended September 30, 2023. The primary reason for the increase in cash provided by our investing activities is proceeds from matured marketable securities of \$5,556,000, net of investment in marketable securities in the nine months ended September 30, 2024, compared to an investment in marketable securities of \$28,838,000, offset by a withdrawal from short-term bank deposits, net of investment in short-term deposits, of \$18,500,000 in the nine months ended September 30, 2023 and by an increase of \$925,000 in payments made for purchase of property, plant and equipment during the nine months ended September 30, 2024.

Cash provided by financing activities for the nine months September 30, 2024, was \$16,889,000. The source of the cash provided by financing activities during the nine months ended September 30, 2024, were the proceeds from exercise of Series H warrants. Cash provided by financing activities for the nine months September 30, 2023, was \$37,534,000. The source of the cash provided by financing activities during the nine months ended September 30, 2023, were the proceeds from the Private Placement Offering in May 2023 that resulted in approximately \$37,534,000 of aggregate net proceeds.

As of September 30, 2024, our current assets exceeded our current liabilities by a multiple of 6.4. Current assets increased by \$2,235,000 during the period and current liabilities increased by \$1,245,000 during the period. As a result, our working capital increased by \$990,000 to \$39,129,000 as of September 30, 2024.

#### **Off Balance Sheet Arrangements**

We have no off-balance sheet transactions, arrangements, obligations (including contingent obligations) or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

#### **Factors That May Affect Future Operations**

We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including the cyclical nature of the ordering patterns of our distributors, timing of regulatory approvals, the implementation of various phases of our clinical trials and manufacturing efficiencies due to the learning curve of utilizing new materials and equipment. Our operating results could also be impacted by a weakening of the Euro and strengthening of the NIS, both against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.

#### **Contractual Obligations and Commitments**

During the nine months ended September 30, 2024, there were no material changes to our contractual obligations and commitments since the year ended December 31, 2023.

#### **Recently Adopted and Issued Accounting Pronouncements**

See Note 3 to our condensed financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for new accounting pronouncements

adopted.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

### Item 4. Controls and Procedures

#### Management's Conclusions Regarding Effectiveness of Disclosure Controls and Procedures

As of September 30, 2024, we conducted an evaluation, under the supervision and participation of management including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective at the reasonable assurance level as of September 30, 2024.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2024, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II - OTHER INFORMATION

### Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or our property that we believe will have any significant effect on our business, financial position or operating results.

#### Item 1A. Risk Factors

Except as set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material changes to our risk factors from those disclosed in "Part I. Item 1A. Risk Factors" in the Form 10-K filed with the SEC on March 5, 2024.

***Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our condensed financial statements for the quarter ended September 30, 2024 includes an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.***

Because we have had recurring losses and negative cash flows from operating activities, substantial doubt exists regarding our ability to remain as a going concern at the same level at which we are currently performing. Accordingly, our condensed financial statements for the quarter ended September 30, 2024 includes an explanatory paragraph as to our potential inability to continue as a going concern. The doubts regarding our potential ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all.

***If there are significant shifts in the political, economic and military conditions in Israel and its neighbors, it could have a material adverse effect on our business relationships and profitability.***

Our executive office, sole manufacturing facility and certain of our key personnel are located in Israel. Our business is directly affected by the political, economic and military conditions in Israel and its neighbors. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors.

In October 2023, Hamas terrorists infiltrated Israel's southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel's border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel's security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israel's northern border with Lebanon (with the Hezbollah terror organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Additionally, Yemeni rebel group, the Houthis, launched series of attacks on global shipping routes in the Red Sea, causing disruptions of supply chain. Such clashes may escalate in the future into a greater regional conflict.

In connection with the Israeli security cabinet's declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service, including five of our full time employees in Israel. Although many of such military reservists have since been released, including the majority of our employees, they may be called up for additional reserve duty, depending on developments in the war in Gaza and along Israel's other borders. Military service call ups that result in absences of personnel from us for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations. As of the date hereof, we currently have 62 full-time employees located in Israel and 18 employees located outside of Israel.

Since the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our clinical studies. None of the clinical sites currently participating in our clinical studies are located in Israel however we currently manufacture our CGuard at our facility in Tel Aviv, Israel. If there were a disruption to our existing manufacturing facility or our ability to procure raw materials and ship our products, we would have no other means of manufacturing and distributing CGuard until we were able to restore the manufacturing and distribution capability at our facility or develop alternative manufacturing facilities and distribution capabilities.

The intensity and duration of the current security situation in Israel is difficult to predict at this stage, as are such war's economic implications on the Company's business and operations and on Israel's economy in general, and we continue to monitor the situation closely and examine the potential disruptions that could adversely affect our operations.

Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.

Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israel's judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.

## Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

## Item 3. Defaults Upon Senior Securities

None.

## Item 4. Mine Safety Disclosures

Not applicable.

## Item 5. Other Information

During the quarter ended September 30, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (in each case, as defined in Item 408 of Regulation S-K).

12

## Item 6. Exhibits

### EXHIBIT INDEX

Exhibit No.	Description
3.1	<a href="#"><u>Amended and Restated Certificate of Incorporation, as amended through March 31, 2015 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015)</u></a>
3.2	<a href="#"><u>Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021)</u></a>
3.3	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on May 25, 2016)</u></a>
3.4	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 29, 2016)</u></a>
3.5	<a href="#"><u>Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 15, 2017)</u></a>
3.6	<a href="#"><u>Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 29, 2017)</u></a>
3.7	<a href="#"><u>Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitation of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on December 12, 2017)</u></a>
3.8	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on February 7, 2018)</u></a>
3.9	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 28, 2019)</u></a>
3.10	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc., dated April 14, 2021 (incorporated by reference to Exhibit 3.17 to the Quarterly Report on Form 10-Q filed on May 10, 2021)</u></a>
3.11	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023)</u></a>
31.1*	<a href="#"><u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u></a>
31.2*	<a href="#"><u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u></a>
32.1*	<a href="#"><u>Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>
32.2*	<a href="#"><u>Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>

101.INS\*      Inline XBRL Instance Document (the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)

101.SCH\*      Inline XBRL Taxonomy Extension Schema Document

101.CAL\*      Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF\*      Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB\*      Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE\*      Inline XBRL Taxonomy Extension Presentation Linkbase Document

104\*            Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

\* Filed herewith.

13

---

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INSPIREMD, INC.

Date: November 12, 2024

By: /s/ Marvin Slosman  
Name: Marvin Slosman,  
Title: President and Chief Executive Officer  
(Principal Executive Officer)

Date: November 12, 2024

By: /s/ Craig Shore  
Name: Craig Shore  
Title: Chief Financial Officer, Secretary and Treasurer  
(Principal Financial and Accounting Officer)

14

---

## CERTIFICATION

I, Marvin Slosman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InspireMD, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2024

/s/ Marvin Slosman  
Marvin Slosman  
Chief Executive Officer  
(Principal Executive Officer)

---

## CERTIFICATION

I, Craig Shore, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of InspireMD, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2024

/s/ Craig Shore

Craig Shore  
Chief Financial Officer, Secretary and Treasurer  
(Principal Financial and Accounting Officer)

---

**CERTIFICATION  
PURSUANT TO  
18 U.S.C. SECTION 1350**

In connection with the Quarterly Report on Form 10-Q of InspireMD, Inc. (the "Company") for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Marvin Slosman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, that, to my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

Date: November 12, 2024

By: /s/ Marvin Slosman

Name: Marvin Slosman

Title: Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION  
PURSUANT TO  
18 U.S.C. SECTION 1350**

In connection with the Quarterly Report on Form 10-Q of InspireMD, Inc. (the "Company") for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Craig Shore, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, that, to my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

Date: November 12, 2024

By: /s/ Craig Shore  
Name: Craig Shore  
Title: Chief Financial Officer, Secretary and Treasurer  
(Principal Financial and Accounting Officer)

---